Regeneron Unveils Pivotal Phase 3 Garetosmab Data in FOP as FDA Priority Review Underway, Alongside Metabolic and Ophthalmology Pipeline Advances
核心洞察
Regeneron presented Week 56 primary analysis from the Phase 3 OPTIMA trial of garetosmab in fibrodysplasia ossificans progressiva (搜索) (FOP) at ENDO 2026, with the FDA already conducting a Priority Review of the BLA.
Three Phase 2 COURAGE trial abstracts at ADA examined trevogrumab, an anti-GDF8 (搜索) antibody, combined with semaglutide to preserve lean mass in people with obesity (搜索), addressing muscle loss associated with GLP-1 receptor agonists.
Preclinical data on REGN24493 (搜索), a novel TSHR (搜索)-blocking monoclonal antibody targeting both Graves' disease (搜索) and thyroid eye disease (搜索), were presented publicly for the first time at ENDO 2026.
Regeneron Pharmaceuticals presented a sweeping portfolio of clinical and preclinical data across two major medical meetings in June 2026, headlined by the pivotal Phase 3 results for garetosmab in fibrodysplasia ossificans progressiva (搜索) (FOP) — a readout that arrives while the FDA is already conducting a Priority Review of the drug's Biologics License Application. The data were featured at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans (June 5–8) and the Endocrine Society Annual Meeting (ENDO 2026) in Chicago (June 13–16).
"Our presentations at ADA and ENDO reflect the rapid progress of our diverse pipeline across diseases where we see both significant unmet need and a real opportunity to make a meaningful impact on patients' lives," said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron.
Garetosmab Phase 3 OPTIMA Data Takes Center Stage at ENDO
The Week 56 efficacy and safety primary analysis from the OPTIMA trial, presented by Richard Keen, MD, in an oral session on June 13, represents the most clinically consequential data disclosure at ENDO. FOP is an ultra-rare genetic disorder in which muscles, tendons, and ligaments are progressively replaced by bone, leaving patients with progressively shrinking mobility. The condition has historically lacked meaningful therapeutic options; palovarotene (Sohonos) only recently became the first approved therapy in the U.S. and Canada.
Garetosmab is an anti-activin A antibody, and the mechanistic coherence of Regeneron's ENDO presentations is notable: three abstracts address the same target from complementary angles. A rapid-fire oral presentation by Aris N. Economides, PhD, demonstrated that blocking activin A prevents heterotopic bone from regrowing after surgical resection in a mouse model of FOP — directly addressing the question of whether intervention can sustain gains long-term. A qualitative interview poster from Jing Gu, PhD, captured OPTIMA trial participants' lived experiences, providing patient-experience evidence that regulators and payers increasingly treat as substantive.
The sequence of a public pivotal data disclosure coinciding with an active Priority Review places every OPTIMA endpoint under immediate regulatory scrutiny. The heterotopic ossification volume change at Week 56 is the single endpoint that will likely define whether the garetosmab BLA review concludes with an approval or a complete response letter.
Trevogrumab and Muscle Preservation in Obesity (搜索) at ADA
At ADA, Regeneron showcased three abstracts from the Phase 2 COURAGE trial investigating trevogrumab, an anti-GDF8 (搜索) (myostatin) antibody, in combination with semaglutide for preserving lean mass in people with obesity (搜索). The clinical concern underpinning this research is well-recognized: weight loss driven by GLP-1 receptor agonists includes a substantial lean-mass component, and at population scale this translates into meaningful muscle loss across a large and growing patient cohort.
Jesse Chao, PharmD, MBA, presented an oral session on the lean mass effects of trevogrumab with or without anti-activin A (garetosmab) in people with obesity (搜索) treated with semaglutide, stratified by baseline lean mass status. Two additional posters addressed methodological considerations: Andrea Vavere, PhD, presented on optimizing DXA imaging in obese populations, and José G. Raya, PhD, examined population-normed Z-scores for body composition to enhance sensitivity and effect size in the COURAGE trial analysis.
Regeneron is positioning the trevogrumab-plus-semaglutide combination as a biologic strategy to address muscle loss, with the DXA imaging optimization work signaling an investment in building the measurement infrastructure needed to establish lean mass as a credible primary endpoint in future registrational trials.
REGN24493 (搜索): A Novel TSHR (搜索) Antibody for Graves' Disease (搜索) and Thyroid Eye Disease (搜索)
Two preclinical abstracts at ENDO introduced REGN24493 (搜索), a TSH-receptor-blocking monoclonal antibody designed to address both Graves' disease (搜索) and thyroid eye disease (搜索) — two conditions driven by shared underlying biology that can cause hyperthyroidism and painful eye protrusion. Mutayyaba Adnan, MPH, presented in-vivo data showing that the TSHR (搜索)-blocking antibody effectively reduces hyperthyroidism and proptosis in a mouse model, while Bristol Denlinger, PhD, presented in-vitro characterization of REGN24493's properties.
These represent the program's first substantive public disclosure. Teprotumumab already holds FDA approval for thyroid eye disease (搜索) via IGF-1 receptor inhibition, meaning Regeneron must establish mechanistic differentiation for REGN24493 (搜索) through the TSH receptor pathway rather than the IGF-1 pathway. The data remain preclinical, with no human signals yet available.
Broader Pipeline Context
An additional ADA poster from Diana Li, PhD, presented early preclinical research showing that double knockout of INHBC and INHBE protects against diet-induced obesity (搜索) and insulin resistance in mice, reflecting Regeneron's broader investment in muscle biology and metabolic health research.
The presentations collectively underscore Regeneron's strategic focus on diseases with significant unmet need, spanning ultra-rare genetic disorders, metabolic disease, and ophthalmology, with the garetosmab FOP program representing the most advanced and near-term regulatory catalyst.